142.37 0.00 (0.00%)
After hours: 4:33PM EDT
|Bid||142.62 x 800|
|Ask||142.62 x 800|
|Day's Range||141.43 - 142.87|
|52 Week Range||109.16 - 157.00|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||22.22|
|Earnings Date||Jul 16, 2020|
|Forward Dividend & Yield||4.04 (2.82%)|
|Ex-Dividend Date||May 22, 2020|
|1y Target Est||164.24|
The U.S. Food and Drug Administration on Friday said it would review GlaxoSmithKline's experimental treatment for multiple myeloma, a common form of blood cancer, for a reported side-effect which affects the eyes of patients. The FDA on Friday published submissions ahead of a meeting of the Oncologic Drugs Advisory Committee (ODAC) on July 14, where they will evaluate how belantamab mafodotin can cause keratopathy, a side-effect where deposits gather on the cornea of the eye. "The concerns and uncertainties regarding the ocular toxicities raises questions about the overall benefit-risk profile of the belantamab mafodotin in the proposed patient population," a briefing document published on the FDA's website said.
Johnson & Johnson is hoping to tackle the new form of coronavirus with a vaccine, but the pharma giant is still facing litigation challenges. Is JNJ stock a buy right now?
Bellwether health care stocks Johnson & Johnson and Abbott Laboratories are widely expected to report earnings crashes next Thursday and declining sales amid the coronavirus pandemic.
Last month six S&P 500 companies said they planned to boost their dividends, against two cuts and one suspension—the first time increases outnumbered cuts since the pandemic forced widespread business lockdowns in March.
The U.S. saw yet another day of record coronavirus casualties on Thursday, led mostly by a relentless surge in the stricken Sun Belt region.
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ISRG stock has dipped this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?
Several prominent plaintiffs' law firms, known for striking large settlements with companies like German carmaker Volkswagen AG and Equifax Inc, were approved for loans that totaled tens of millions of dollars in government aid meant to help small businesses stay afloat during the coronavirus pandemic. San Francisco-based Lieff Cabraser Heimann & Bernstein, which has 100 lawyers and bills itself on its website as "among the largest law firms in the United States that only represent plaintiffs" was approved to receive between $2 million and $5 million under the Paycheck Protection Program, according to data released Monday by the U.S. Treasury Department and Small Business Administration. Steven Fineman, the firm's managing partner, said Lieff Cabraser used the loan to compensate lawyers and staff members and prevent layoffs.
The groups, which include educational institutions such as Emory University and activist groups such as Greenpeace, among others, also want the company to recall existing inventory in North America. Janette Robinson Flint, the executive director of Black Women for Wellness, said in a statement that J&J's choice to continue marketing baby powder in international markets, often to Black and Brown consumers, contradicts a statement it issued in June committing to fighting racial inequality.
The United States will potentially have tens of millions of doses of experimental COVID-19 vaccines available by this fall and hundreds of millions of doses by the beginning of 2021, a top health official said on Thursday. U.S. Department of Health and Human Services Secretary Alex Azar on Thursday said during an internet interview with The Hill that the early doses would be the result of government funding to scale up manufacturing ahead of the vaccines being approved by regulators. The government has provided billions of dollars for vaccines under development at Moderna, Johnson & Johnson , AstraZeneca and Novavax.
U.S. drugmaker Johnson & Johnson aims to begin clinical testing of its COVID-19 vaccine in the coming weeks and produce billions of doses in 2021, chief executive officer Alex Gorsky said on Wednesday, but cautioned that it will take more than one vaccine to rein in the virus. Gorsky said it was a good thing other companies are experimenting with different approaches to vaccines, in part because different vaccines might work better in different groups of people. "I think it's going to take multiple vaccines."
The U.S. topped 3 million coronavirus cases Wednesday after setting a new record of 60,000 daily cases in the previous day.
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dr. Fauci says he expects phase 3 vaccine trials to begin at the end of July. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss where vaccine trials stand.
The midcap drugmaker said Wednesday it would collaborate with the Mount Sinai Health System to test a drug derived from blood plasma taken from recovered Covid-19 patients.
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021. The award is the biggest yet from "Operation Warp Speed", the White House program aimed at accelerating access to vaccines and treatments to fight the coronavirus that causes COVID-19. "What this Warp Speed award does is it pays for production of 100 million doses, which would be delivered starting in the fourth quarter of this year, and may be completed by January or February of next year," Novavax Chief Executive Stanley Erck told Reuters.
These 15 dividend stock picks, satisfying income investing needs of every kind, have so far kept their payouts intact while many big firms have cut back.
Moody's Investors Service, ("Moody's") assigned a Baa3 rating to Jabil Inc.'s ("Jabil") proposed senior unsecured note offering. The refinancing of the $400 million of 5.625% notes due December 2020 addresses a near term maturity and increases the amount of debt maturing in two years or more to roughly 88% of Jabil's debt capital.
A plant in Italy owned by U.S. group Catalent will help produce the potential COVID-19 vaccine being developed by drugmaker Johnson & Johnson, Italian Health minister Roberto Speranza said on Monday. "It is today's news that the vaccine Johnson & Johnson is working on will also be completed here," the minister said during a visit to the site in Anagni, a town 70 km from Italian capital Rome. The plan to produce the potential vaccine in Italy represents an expansion of an existing deal between the two American companies.
The Stop TB Partnership and Johnson & Johnson (NYSE: JNJ) – with support from the Global Fund to Fight AIDS, TB and Malaria, and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines.